Blood Pressure, Volume 9, Issue sup1 (2000)

Browse this journal
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Blood Pressure, Volume 9, Issue sup1 (2000)

See all volumes and issues
Vol 33, 2024 Vol 32, 2023 Vol 31, 2022 Vol 30, 2021 Vol 29, 2020 Vol 28, 2019 Vol 27, 2018 Vol 26, 2017 Vol 25, 2016 Vol 24, 2015 Vol 23, 2014 Vol 22, 2013 Vol 21, 2012 Vol 20, 2011 Vol 19, 2010 Vol 18, 2009 Vol 17, 2008 Vol 16, 2007 Vol 15, 2006 Vol 14, 2005 Vol 13, 2004 Vol 12, 2003 Vol 11, 2002 Vol 10, 2001 Volume 9, 2000 Vol 8, 1999 Vol 7, 1998 Vol 6, 1997 Vol 5, 1996 Vol 4, 1995 Vol 3, 1994 Vol 2, 1993 Vol 1, 1992
Download citations Download PDFs Download issue

Research Article

Article
The Renin-Angiotensin System and Cardiovascular Disease
NORMAN K. HOLLENBERG
Pages: 5-8
Published online: 08 Jul 2009
AbstractforThe Renin-Angiotensin System and Cardiovascular Disease | References | PDF (105 KB)
  • 60 Views
  • 11 CrossRef citations
  • 0Altmetric
Free Access
Article
Angiotensin II Type 1 Receptor Blockade: a Novel Therapeutic Concept
COLIN I. JOHNSTON
Pages: 9-13
Published online: 08 Jul 2009
AbstractforAngiotensin II Type 1 Receptor Blockade: a Novel Therapeutic Concept | References | PDF (171.2 KB)
  • 76 Views
  • 16 CrossRef citations
  • 0Altmetric
Free Access
Article
Differences Among Angiotensin II Type 1 Receptor Blockers: Characteristics of Candesartan Cilexetil
THOMAS UNGER
Pages: 14-18
Published online: 08 Jul 2009
AbstractforDifferences Among Angiotensin II Type 1 Receptor Blockers: Characteristics of Candesartan Cilexetil | References | PDF (242.2 KB)
  • 131 Views
  • 7 CrossRef citations
  • 0Altmetric
Free Access
Article
Improving Antihypertensive Efficacy while Maintaining Placebo-like Tolerability
PETER S. SEVER
Pages: 19-22
Published online: 08 Jul 2009
AbstractforImproving Antihypertensive Efficacy while Maintaining Placebo-like Tolerability | References | PDF (113.3 KB)
  • 65 Views
  • 2 CrossRef citations
  • 0Altmetric
Free Access
Article
Achieving Quality 24-h Blood Pressure Control with Candesartan Cilexetil
PETER MEREDITH
Pages: 23-26
Published online: 08 Jul 2009
AbstractforAchieving Quality 24-h Blood Pressure Control with Candesartan Cilexetil | References | PDF (147.5 KB)
  • 103 Views
  • 8 CrossRef citations
  • 0Altmetric
Free Access
Article
Efficacy and Tolerability of Candesartan Cilexetil in Special Patient Groups
PETER TRENKWALDER
Pages: 27-30
Published online: 08 Jul 2009
AbstractforEfficacy and Tolerability of Candesartan Cilexetil in Special Patient Groups | References | PDF (84.5 KB)
  • 107 Views
  • 11 CrossRef citations
  • 0Altmetric
Free Access
Article
Improving Prognosis in Hypertension: Exploring the Benefits of Angiotensin II Type 1 Receptor Blockade
LUIS RUILOPE
Pages: 31-35
Published online: 08 Jul 2009
AbstractforImproving Prognosis in Hypertension: Exploring the Benefits of Angiotensin II Type 1 Receptor Blockade | References | PDF (143 KB)
  • 30 Views
  • 6 CrossRef citations
  • 0Altmetric
Free Access
Article
Preserving Target-organ Function with Candesartan Cilexetil in Patients with Hypertension
FAIEZ ZANNAD
Pages: 36-39
Published online: 08 Jul 2009
AbstractforPreserving Target-organ Function with Candesartan Cilexetil in Patients with Hypertension | References | PDF (135.8 KB)
  • 54 Views
  • 7 CrossRef citations
  • 0Altmetric
Free Access
Article
Reducing Cardiovascular Morbidity and Mortality in the Elderly
PETER TRENKWALDER
Pages: 40-43
Published online: 08 Jul 2009
AbstractforReducing Cardiovascular Morbidity and Mortality in the Elderly | References | PDF (131.5 KB)
  • 66 Views
  • 4 CrossRef citations
  • 0Altmetric
Free Access
Article
Exploring New Treatment Strategies in Heart Failure
KARL SWEDBERG
Pages: 44-48
Published online: 08 Jul 2009
AbstractforExploring New Treatment Strategies in Heart Failure | References | PDF (165.3 KB)
  • 37 Views
  • 2 CrossRef citations
  • 0Altmetric
Free Access
Article
Candesartan, an Insurmountable Antagonist of Angiotensin II-mediated Contractile Effects in Isolated Vascular Preparations: Comparison with Irbesartan, Losartan and its Active Metabolite (EXP-3174)
P. MORSING, U. BRANDT-ELIASSON, L. RENBERG, T. ABRAHAMSSON
Pages: 50-51
Published online: 08 Jul 2009
AbstractforCandesartan, an Insurmountable Antagonist of Angiotensin II-mediated Contractile Effects in Isolated Vascular Preparations: Comparison with Irbesartan, Losartan and its Active Metabolite (EXP-3174) | PDF (27.4 KB)
  • 75 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access
Article
Candesartan Causes Long-lasting Antagonism of the Angiotensin II Receptor-mediated Contractile Effects in Isolated Vascular Preparations: a Comparison with Irbesartan, Losartan and its Active Metabolite (EXP-3174)
T. ABRAHAMSSON,L. KARP,U. BRANDT-ELIASSON,P. MORSING,L. RENBERG,P.-O. SJÖQUIST
Page: 52
Published online: 08 Jul 2009
AbstractforCandesartan Causes Long-lasting Antagonism of the Angiotensin II Receptor-mediated Contractile Effects in Isolated Vascular Preparations: a Comparison with Irbesartan, Losartan and its Active Metabolite (EXP-3174) | PDF (17.4 KB)
  • 48 Views
  • 1 CrossRef citations
  • 0Altmetric
Free Access
Article
Is it Possible to Differentiate between Angiotensin II Type 1 (AT1) Receptor Blockers in Normotensive Volunteers?
M. AZIZI,G. CHATELLIER,L. NICOLET,T. GUYENE,J. HEMPENIUS,J. MÉNARD
Page: 53
Published online: 08 Jul 2009
AbstractforIs it Possible to Differentiate between Angiotensin II Type 1 (AT1) Receptor Blockers in Normotensive Volunteers? | PDF (23.5 KB)
  • 38 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access
Article
Candesartan Cilexetil, a Novel Angiotensin II Antagonist, Provides Dose-dependent Antihypertensive Effect with Maintained Tolerability
D. ELMFELDT,M. GEORGE,R. HÜBNER,B. OLOFSSON
Page: 54
Published online: 08 Jul 2009
AbstractforCandesartan Cilexetil, a Novel Angiotensin II Antagonist, Provides Dose-dependent Antihypertensive Effect with Maintained Tolerability | PDF (21.7 KB)
  • 81 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access
Article
Candesartan Cilexetil, 16 mg, Provides a Greater Antihypertensive Effect than Losartan, 50 mg, in Patients with Mild to Moderate Hypertension
S. NELDAM & O. K. ANDERSSON,
Page: 55
Published online: 08 Jul 2009
AbstractforCandesartan Cilexetil, 16 mg, Provides a Greater Antihypertensive Effect than Losartan, 50 mg, in Patients with Mild to Moderate Hypertension | PDF (24.8 KB)
  • 95 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access
Article
Candesartan Cilexetil is not Associated with Cough in Patients with Enalapril-induced Cough
P. TANSER,L. M. CAMPBELL,J. CARRANZA,J. KARRASCH,P. TOUTOUZAS,R. WATTS
Page: 56
Published online: 08 Jul 2009
AbstractforCandesartan Cilexetil is not Associated with Cough in Patients with Enalapril-induced Cough | PDF (24.2 KB)
  • 65 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access
Article
Candesartan Cilexetil, a Novel Angiotensin II Type 1 (AT1) Receptor Blocker, Reduces Microalbuminuria in Patients with Type II Diabetes Mellitus and Mild Hypertension
P. TRENKWALDER,K. DAHL,M. LEHTOVIRTA,H. MULDER
Page: 57
Published online: 08 Jul 2009
AbstractforCandesartan Cilexetil, a Novel Angiotensin II Type 1 (AT1) Receptor Blocker, Reduces Microalbuminuria in Patients with Type II Diabetes Mellitus and Mild Hypertension | PDF (22.3 KB)
  • 56 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access
Article
Antihypertensive Effects and Tolerability of Candesartan Cilexetil in an Elderly Population
J. JONKER & G. T. MCINNES,
Page: 58
Published online: 08 Jul 2009
AbstractforAntihypertensive Effects and Tolerability of Candesartan Cilexetil in an Elderly Population | PDF (19.1 KB)
  • 64 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access
Article
Study on COgnition and Prognosis in the Elderly (SCOPE): Design and Objectives
L. HANSSON
Page: 59
Published online: 08 Jul 2009
AbstractforStudy on COgnition and Prognosis in the Elderly (SCOPE): Design and Objectives | PDF (22.4 KB)
  • 91 Views
  • 7 CrossRef citations
  • 0Altmetric
Free Access
Article
Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity (CHARM) Study Programme
K. SWEDBERG,M. PFEFFER,G. B. GRANGER,J. McMURRAY,S. YUSUF
Page: 60
Published online: 08 Jul 2009
AbstractforCandesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity (CHARM) Study Programme | PDF (22.8 KB)
  • 139 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access
Article
A Combination of Candesartan Cilexetil/hydrochlorothiazide (HCTZ), 8/12.5 mg, has a Similar Antihypertensive Efficacy and is Better Tolerated than Lisinopril/HCTZ, 10/12.5 mg
G. T. McINNES,H. ISTAD,S. KEINÄNEN-KIUKAANNIEMI,H. F. C. M. VAN MIERLO
Page: 61
Published online: 08 Jul 2009
AbstractforA Combination of Candesartan Cilexetil/hydrochlorothiazide (HCTZ), 8/12.5 mg, has a Similar Antihypertensive Efficacy and is Better Tolerated than Lisinopril/HCTZ, 10/12.5 mg | PDF (23.4 KB)
  • 54 Views
  • 1 CrossRef citations
  • 0Altmetric
Free Access

Explore articles